Kentucky blocks pharmacies from compounding BPC-157, TB-500 and four other peptides
a state rule on compounding for human use, Kentucky only
The state's pharmacy board says the federal enforcement pause on six peptides does not override Kentucky law, and it will not grant waivers.
What happened
On November 18, 2026, the Kentucky Board of Pharmacy voted to enforce its compounding rule, 201 KAR 2:076, as written, and to decline waivers for six peptide bulk drug substances. It posted a compliance alert to every pharmacy permit holder on November 19.
The six are BPC-157, TB-500 (the thymosin beta-4 fragment), Epitalon, Semax, KPV and MOTS-c. These are the same six named in the federal enforcement discretion policy that HHS published on October 30, 2026.
How it works
Kentucky's rule says a compounded preparation for people must meet a USP or National Formulary monograph, come from a component of an FDA-approved drug, or come from a substance on FDA's list of bulk drug substances. The board says none of the six meets any of those, so their use in compounding in Kentucky has never been authorized.
The board reads the federal policy as a statement of enforcement priorities only. In its words it does not approve the substances, does not add them to FDA's bulks list and does not displace state law.
What it means for you
Pharmacies may not compound, dispense or ship preparations made from these six peptides to patients or prescribers in Kentucky. That includes nonresident pharmacies that hold a Kentucky permit, so out-of-state compounders cannot ship them in either.
Pharmacies have to set aside any stock of these substances or finished preparations, keep it out of active inventory and dispose of it. They are told not to fill new prescriptions and to talk the prescriber through other options. If you get one of these peptides from a compounding pharmacy and live in Kentucky, expect that supply to stop.
What's next
The board says it will tell licensees if FDA adds any of the six to its list of bulk drug substances. Until then the rule holds, and a violation can cost a pharmacy its license, a fine or probation. Other states have not announced the same step yet.
The numbers
- Vote: November 18, 2026; compliance alert posted November 19, 2026
- Six peptides: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c
- No waivers; existing stock set aside and disposed of
- Applies to nonresident pharmacies permitted in Kentucky too
- HHS enforcement discretion policy: October 30, 2026 (91 Fed. Reg. 68526)
The original: Kentucky Board of Pharmacy (compliance alert)